FDA Approves NerPharMa to Manufacture Cell Therapeutics Drug Pixantrone
Cell Therapeutics, 03/09/2010
Free full text
Cell Therapeutics, Inc. announced that the U.S. Food and Drug Administration has completed its inspection of the facility at NerPharMa, which manufactures the CTI's drug pixantrone and has found the site in compliance and acceptable for continued manufacturing of the drug product. CTI has a New Drug Application under review at the FDA for pixantrone to treat relapsed/refractory aggressive non–Hodgkin's lymphoma.







